[ad_1]
The Food and Drug Administration (FDA) has approved the first drug for the treatment of children with SLE.
The agency said in a statement posted on its website that the new drug is called "Benlysta" Benlysta. It is an injection injected into the vein.
She added that SLE is a serious chronic immune disease that causes inflammation and damage to various tissues and organs of the body.
The disease comes in the form of a red rash on the cheeks and on the bridge of the nose, as well as an inflammation of many organs and organs of the body.
The FDA noted that this was the first time that she approved a treatment for children with SLE, in 2011 she approved the same drug but treated adults with the disease.
The FDA approval comes after a study of 93 children with lupus erythematosus and was treated for 52 weeks.
The results showed that children who received the drug were less likely to develop a rash than their counterparts on placebo.
And among the most common side effects of the drug, the Board noted that it included nausea, diarrhea and fever.
The word lupus is due to the appearance of skin lesions similar to the bite marks and is a rare sign on the skin, especially for this disease.
According to the authorities, the incidence of children with lupus erythematosus is rare, but when diagnosed, the disease affects limbs such as the kidneys and the central nervous system.
Because of the disease, children with lupus are more likely to have greater damage and complications in their organs.
[ad_2]
Source link
